Literature DB >> 17586562

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.

Louis D Saravolatz1, Joan Pawlak, Leonard B Johnson.   

Abstract

OBJECTIVES: This study compared the activity of telavancin, a novel multivalent lipoglycopeptide with rapid bactericidal activity, with those of five standard antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) against isolates of community-associated MRSA (CA-MRSA).
METHODS: Microdilution tests performed according to CLSI guidelines using cation-adjusted Mueller-Hinton broth were used to determine the MIC values of telavancin, quinupristin/dalfopristin, vancomycin, trimethoprim/sulfamethoxazole, linezolid and daptomycin versus 60 CA-MRSA isolates. MBC values of telavancin were determined according to CLSI guidelines and American Society for Microbiology standards. PFGE was performed using the restriction enzyme SmaI. Samples from three predominant pulsed-field types were typed by multilocus sequence typing. Staphylococcal cassette chromosome mec typing was determined by multiplex PCR. The Panton-Valentine leucocidin (PVL) genes (lukS-PV and lukF-PV) were identified by PCR.
RESULTS: The telavancin MIC90 and MBC90 values for this collection of 60 CA-MRSA isolates were 0.5 and 1 mg/L, respectively, with MIC and MBC values both ranging from 0.25 to 1 mg/L. Telavancin was found to be bactericidal in this study, as its MBC was no more than 2-fold higher than its MIC for all CA-MRSA isolates tested except one. (A single isolate yielded an MBC/MIC ratio of 4.) PVL- and non-PVL-producing strains demonstrated similar susceptibility to telavancin and comparator agents.
CONCLUSIONS: Based on in vitro activity, telavancin should be an effective agent against CA-MRSA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17586562     DOI: 10.1093/jac/dkm211

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

2.  Telavancin.

Authors:  Katherine A Lyseng-Williamson; Stephanie K A Blick
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 3.  Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.

Authors:  Adamantia Liapikou; Katerina Dimakou; Michael Toumbis
Journal:  Ther Adv Respir Dis       Date:  2016-06-23       Impact factor: 4.031

4.  Transplacental transfer of vancomycin and telavancin.

Authors:  Tatiana Nanovskaya; Svetlana Patrikeeva; Ying Zhan; Valentina Fokina; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Am J Obstet Gynecol       Date:  2012-08-04       Impact factor: 8.661

5.  Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.

Authors:  Rabih O Darouiche; Mohammad D Mansouri; Marlowe J Schneidkraut
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

6.  In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.

Authors:  Sydney M Finegold; Mauricio Bolanos; Paula H Sumannen; Denise R Molitoris
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

7.  Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus.

Authors:  William J Peppard; Anne Daniels; Lynne Fehrenbacher; Jamie Winner
Journal:  Infect Drug Resist       Date:  2009-06-08       Impact factor: 4.003

8.  Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.

Authors:  Jennifer I Smart; Gordon Ralph Corey; Martin E Stryjewski; Whedy Wang; Steven L Barriere
Journal:  Infect Dis Ther       Date:  2016-10-07

Review 9.  Antibiotics and Carbohydrate-Containing Drugs Targeting Bacterial Cell Envelopes: An Overview.

Authors:  Federico Riu; Alessandro Ruda; Roberta Ibba; Simona Sestito; Ilenia Lupinu; Sandra Piras; Göran Widmalm; Antonio Carta
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-29

10.  A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).

Authors:  Lala M Dunbar; Derek M Tang; Robert M Manausa
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.